Dermorphinis a naturally occurringheptapeptide(Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂) first isolated from the skin of South AmericanPhyllomedusafrogs. Unlike conventional opioids, Dermorphin incorporates aD-amino acid (D-Ala)at position 2, which contributes to itsexceptionally high affinityfor μ-opioid receptors andresistance to enzymatic degradation. It is estimated to be30–40 times more potent than morphinewith longer-lasting analgesia and a slower onset of tolerance.
While never commercialized for medical use, Dermorphin has been studied for itsintrathecal analgesic properties,potential for chronic pain management, and has controversially appeared inracehorse dopingdue to its profound pain-masking effects.
Dermorphin exerts its effects primarily through the μ-opioid receptor (MOR):
Acts as a high-affinity MOR agonist, activating Gi/o protein-coupled signaling pathways
Inhibits adenylyl cyclase activity, reduces cAMP levels, and decreases calcium influx, resulting in neural hyperpolarization and antinociception
The presence of D-Ala allows the peptide to resist peptidase activity and extend receptor binding duration
Triggers strong descending inhibitory modulation of pain, particularly in spinal and supraspinal centers
Preclinical and Clinical Studies:
In rodent models, Dermorphin demonstrates ED₅₀ values in the picomole range with potent, dose-dependent antinociception
Compared to morphine, it induces less respiratory depression and slower development of tolerance
Human clinical trials from the 1980s found intrathecal Dermorphin (20 μg) to provide significantly longer analgesia (up to 43 hours) than morphine (500 μg)
Peripheral analogs (e.g., [D-Arg²]dermorphin) show efficacy in inflammatory and neuropathic pain models with minimal CNS side effects
Modern interest in Dermorphin includes its potential as a template for novel opioid peptides with improved safety profiles
Intended Use:
The information provided on this site is intended exclusively for educational and research purposes and should not be interpreted as medical guidance.
Research compounds, including Dermorphin, are designed solely for laboratory investigation by qualified professionals and are not intended for human use or consumption.
The statements presented here have not been evaluated by the U.S. Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease.
Choosing a selection results in a full page refresh.
